World's Best Scientists 2026 revealed!
Marjatta Leirisalo-Repo

Marjatta Leirisalo-Repo

D-Index & Metrics

Medicine

D-Index
78
Citations
24322
World Ranking
17982
National Ranking
202

Marjatta Leirisalo-Repo publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marjatta Leirisalo-Repo sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 377 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marjatta Leirisalo-Repo D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marjatta Leirisalo-Repo sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marjatta Leirisalo-Repo is affiliated with the University of Helsinki in Finland and has a research focus primarily in the field of Medicine, with a strong emphasis on Rheumatology. Their work spans several subfields including Genetics, Hematology, Radiology, Nuclear Medicine and Imaging, and Cardiology and Cardiovascular Medicine.

The scientist's research topics cover a variety of areas within biomedical science, notably:

  • Rheumatoid Arthritis Research and Therapies
  • Autoimmune and Inflammatory Disorders Research
  • Chronic Lymphocytic Leukemia Research
  • Systemic Lupus Erythematosus Research
  • Monoclonal and Polyclonal Antibodies Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Spondyloarthritis Studies and Treatments

Leirisalo-Repo has contributed to multiple publications in renowned journals. Frequent publication venues include:

  • Scandinavian Journal of Rheumatology
  • Annals of the Rheumatic Diseases
  • Frontiers in Immunology
  • Arthritis Research & Therapy
  • Clinical & Experimental Immunology

Selected recent papers authored or co-authored by Leirisalo-Repo are:

  • "Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response," 2021, Frontiers in Immunology
  • "Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial," 2023, Annals of the Rheumatic Diseases
  • "The biological activity of serum bacterial lipopolysaccharides associates with disease activity and likelihood of achieving remission in patients with rheumatoid arthritis," 2022, Arthritis Research & Therapy
  • "Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response," 2022, Clinical & Experimental Immunology
  • "Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature," 2020, Frontiers in Immunology

Frequent collaborators in their research include:

  • Ritva Peltomaa
  • Riitta Koivuniemi
  • Pia Isomäki
  • Tiina Kelkka
  • Paula Savola

Best Publications

  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J Braun;R van den Berg;X Baraliakos;H Boehm

  • Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial

    Timo Möttönen;Pekka Hannonen;Marjatta Leirisalo-Repo;Martti Nissilä

  • The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

    M Rudwaleit;R Landewé;D van der Heijde;J Listing

  • ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J. Zochling;D. Van Der Heijde;R. Burgos-Vargas;E. Collantes

  • New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)

    J. Sieper;D.M. Van der Heijde;RB Landewe;J. Brandt

  • Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

    Timo Möttönen;Pekka Hannonen;Markku Korpela;Martti Nissilä

  • SULFASALAZINE IN THE TREATMENT OF SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY.

    Maxime Dougados;Sjef Van Der Linden;Marjatta Leirisalo‐Repo;Bernhard Huitfeldt

  • Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus

    O. Vaarala;K. Aho;T. Palosuo;G. Alfthan

  • 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

    J. Braun;R. Van Den Berg;X. Baraliakos;H. Boehm

  • Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs : five-year experience from the FIN-RACo study

    Markku Korpela;Leena Laasonen;Pekka Hannonen;Hannu Kautiainen

  • Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

    A Calin;B A C Dijkmans;P Emery;M Hakala

  • Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components

    Maxime Dougados;Bernard Combe;Alain Cantagrel;Philippe Goupille

  • Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis

    Anneli Lauhio;Marjatta Leirisalo-Repo;Juhani Lähdevirta;Pekka Saikku

  • Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.

    Kari Puolakka;Hannu Kautiainen;Timo Möttönen;Pekka Hannonen

  • Impaired Responsiveness to NO in Newly Diagnosed Patients With Rheumatoid Arthritis

    Robert Bergholm;Marjatta Leirisalo-Repo;Satu Vehkavaara;Sari Mäkimattila

  • Campylobacter-triggered reactive arthritis: a population-based study.

    T. Hannu;L. Mattila;H. Rautelin;P. Pelkonen

  • High frequency of silent inflammatory bowel disease in spondylarthropathy.

    Marjatta Leirisalo-Repo;Ulla Turunen;Svante Stenman;Petri Helenius

  • Annual incidence of inflammatory joint diseases in a population based study in southern Sweden

    Maria Söderlin;Olle Börjesson;Hannu Kautiainen;Thomas Skogh

  • Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy.

    Lehtinen A;Taavitsainen M;Leirisalo-Repo M

  • Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis.

    Rainer H. Straub;Leena Paimela;Ritva Peltomaa;Jürgen Schölmerich

Frequent Co-Authors

Hannu Kautiainen
Hannu Kautiainen University of Helsinki
Anja Siitonen
Anja Siitonen Finnish Institute for Health and Welfare (THL)
Maxime Dougados
Maxime Dougados Hôpital Cochin
Kaisa Granfors
Kaisa Granfors University of Turku
Eeva Moilanen
Eeva Moilanen Tampere University
Paul Emery
Paul Emery University of Leeds
Jukka H. Meurman
Jukka H. Meurman University of Helsinki
Robert Landewé
Robert Landewé University of Amsterdam
Herman Mielants
Herman Mielants Ghent University Hospital
Satu Mustjoki
Satu Mustjoki University of Helsinki

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to a wide range of rewarding careers in healthcare. Many students consider alternative or related pathways that provide flexibility and strong job prospects. For example, aspiring nurses might be interested in exploring nursing schools that don't require teas, which can simplify the admissions process and get you started on your career sooner.

If leadership and management interests you, there are excellent options for those looking for healthcare administration degrees. These programs are ideal for individuals who want to oversee operations in clinical settings or health organizations.

Registered nurses aiming for advanced practice roles might consider adn to fnp bridge programs, which help transition from an associate degree in nursing to a master's degree and family nurse practitioner certification.

For those interested in preventative health and diet, an online bachelor's degree in nutrition could provide a pathway to roles in wellness coaching, clinical nutrition, or public health.

Best Scientists Citing Marjatta Leirisalo-Repo

Trending Scientists

Recently Published Articles